Zhejiang Shengda Pharm603079
▼ NegativeCapitalrelevance
Net profit down 45.70% in interim report
Impact on stocks 1
Others
Zhejiang Shengda PharmShengda Bio released its 2026 interim report. Total operating revenue was 389 million yuan, down 2.91% year on year. Net profit attributable to the parent company was 20.5275 million yuan, down 45.70% from the same period last year. Net cash flow from operating activities was 10.7285 million yuan, down 53.28% year on year. The company's asset-liability ratio was 28.47%, gross margin was 27.87%, ROE was 1.29%, and diluted earnings per share was 0.11 yuan.
Zhejiang Shengda PharmNet profit down 45.70% in interim report